Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:JUSHF NASDAQ:MNMD OTCMKTS:MRMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJUSHFJushi$0.66+1.3%$0.42$0.22▼$0.98$129.48M-0.98237,343 shs455,027 shsMNMDMind Medicine (MindMed)$9.72-2.5%$8.22$4.70▼$10.49$739.58M2.491.51 million shs882,014 shsMRMDMariMed$0.13$0.09$0.07▼$0.29$50.76M3.02474,509 shs2.82 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJUSHFJushi-3.94%+3.16%+42.00%+91.02%+0.78%MNMDMind Medicine (MindMed)-1.77%+0.81%+19.69%+52.21%+51.29%MRMDMariMed+11.02%+19.27%+32.11%+66.24%-49.44%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationJUSHFJushi1.9037 of 5 stars0.05.00.00.03.31.70.6MNMDMind Medicine (MindMed)2.6898 of 5 stars3.63.00.00.02.80.80.6MRMDMariMed1.3363 of 5 stars0.05.00.00.02.60.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJUSHFJushi 1.00SellN/AN/AMNMDMind Medicine (MindMed) 3.22Buy$24.71154.13% UpsideMRMDMariMed 4.00Strong BuyN/AN/ACurrent Analyst Ratings BreakdownLatest MRMD, MNMD, and JUSHF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/4/2025MNMDMind Medicine (MindMed)OppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$25.008/1/2025MNMDMind Medicine (MindMed)Chardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJUSHFJushi$257.52M0.51N/AN/A($0.40) per share-1.68MNMDMind Medicine (MindMed)N/AN/AN/AN/A$2.44 per shareN/AMRMDMariMed$157.96M0.32$0.02 per share5.43$0.15 per share0.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJUSHFJushi-$48.78M-$0.29N/AN/AN/A-22.56%N/A-13.23%N/AMNMDMind Medicine (MindMed)-$108.68M-$1.53N/AN/AN/AN/A-50.24%-39.41%N/AMRMDMariMed-$12.16M-$0.03N/A∞N/A-10.14%-10.52%-3.10%N/ALatest MRMD, MNMD, and JUSHF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025JUSHFJushi-$0.06-$0.06N/A-$0.06$64.67 million$65.05 million7/31/2025Q2 2025MNMDMind Medicine (MindMed)-$0.38-$0.50-$0.12-$0.50N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthJUSHFJushiN/AN/AN/AN/AN/AMNMDMind Medicine (MindMed)N/AN/AN/AN/AN/AMRMDMariMedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJUSHFJushiN/A1.020.48MNMDMind Medicine (MindMed)0.224.984.98MRMDMariMed1.251.120.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJUSHFJushi21.68%MNMDMind Medicine (MindMed)27.91%MRMDMariMed0.18%Insider OwnershipCompanyInsider OwnershipJUSHFJushi22.48%MNMDMind Medicine (MindMed)2.45%MRMDMariMed18.99%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJUSHFJushi1,234196.63 million152.43 millionNot OptionableMNMDMind Medicine (MindMed)4076.09 million74.22 millionOptionableMRMDMariMed260390.43 million316.29 millionNot OptionableMRMD, MNMD, and JUSHF HeadlinesRecent News About These CompaniesDespite Fast-paced Momentum, MariMed Inc. (MRMD) Is Still a Bargain StockAugust 14 at 9:50 AM | zacks.com4 Medical Product Stocks to Watch From a Challenging IndustryAugust 14 at 9:36 AM | zacks.comMariMed Earnings Call: Growth Amidst ChallengesAugust 13 at 2:46 AM | msn.comMariMed Inc. (MRMD) Q2 2025 Earnings Call TranscriptAugust 7, 2025 | seekingalpha.comMariMed (MRMD) Q2 EPS Jumps to PositiveAugust 6, 2025 | fool.comMariMed Inc. (MRMD) Reports Break-Even Earnings for Q2August 6, 2025 | zacks.comMariMed Reports Second Quarter 2025 EarningsAugust 6, 2025 | globenewswire.comMariMed (MRMD) Projected to Post Quarterly Earnings on WednesdayAugust 5, 2025 | americanbankingnews.comMariMed’s Products to Enter Pennsylvania Market Through a Management Services and Licensing Agreement with TILT HoldingsJuly 31, 2025 | finance.yahoo.comMariMed's Products to Enter Pennsylvania Market Through a Management Services and Licensing Agreement with TILT HoldingsJuly 31, 2025 | globenewswire.comCORRECTION -- MariMed Expands Access to Top-Selling Betty’s Eddies Brand in MaineJuly 14, 2025 | uk.finance.yahoo.comMariMed Expands Access to Top-Selling Betty’s Eddies Brand in MaineJuly 14, 2025 | finance.yahoo.comCORRECTION -- MariMed Expands Access to Top-Selling Betty's Eddies Brand in MaineJuly 14, 2025 | globenewswire.comMariMed Expands Access to Top-Selling Betty's Eddies Brand in MaineJuly 14, 2025 | globenewswire.comMariMed Expands Access to Top-Selling Betty's Eddies Brand in MaineJuly 14, 2025 | globenewswire.comMariMed Announces Second Quarter 2025 Earnings DateJuly 8, 2025 | globenewswire.comMariMed Statement Regarding the Commencement of Adult-Use Cannabis Sales in Delaware on August 1stJuly 1, 2025 | globenewswire.comMariMed Inc. (MRMD) Latest Stock News & Headlines - Yahoo FinanceJune 24, 2025 | finance.yahoo.comMariMed’s Premium Nature’s Heritage Brand Enters Functional Mushroom Market Launching Plant-Based MycroDoseMay 29, 2025 | uk.finance.yahoo.comMariMed's Premium Nature's Heritage Brand Enters Functional Mushroom Market Launching Plant-Based MycroDoseMay 29, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRMD, MNMD, and JUSHF Company DescriptionsJushi OTCMKTS:JUSHF$0.66 +0.01 (+1.29%) As of 03:59 PM EasternJushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for medical and adult-use markets. The company offers flower, extracts, concentrates, edibles, oil, pre-rolls, tinctures, capsules, softgels, cannabis-infused gummies and ultra-premium chocolate, and topicals products, as well as vaporization devices and cartridges under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. It is also involved in the bulk wholesale of refined cannabinoids and terpenes. In addition, the company operates medical cannabis dispensaries under the BEYOND/HELLO, Nature's Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. The company is headquartered in Boca Raton, Florida.Mind Medicine (MindMed) NASDAQ:MNMD$9.72 -0.25 (-2.51%) Closing price 04:00 PM EasternExtended Trading$9.74 +0.02 (+0.26%) As of 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.MariMed OTCMKTS:MRMD$0.13 0.00 (0.00%) As of 03:49 PM EasternMariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature's Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty's Eddies brand and ice creams under Emack & Bolio's brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore Brinker Serves Up Earnings Beat, Sidesteps Cost Pressures CAVA’s Honeymoon Ends With a 16% Stock Drop Rigetti Stock: A Long-Term Quantum Play Facing Short-Term Tests 5 Stocks Insiders Are Selling That Analysts Say Buy CoreWeave Pulls Back Into a Screaming Buy Amazon’s Bears Have Raised the White Flag—Get Excited Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access